Arcadia Biosciences, Inc. (NASDAQ:RKDA – Get Free Report) passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $0.60 and traded as low as $0.4501. Arcadia Biosciences shares last traded at $0.4797, with a volume of 34,400 shares traded.
Analyst Ratings Changes
Separately, Weiss Ratings downgraded Arcadia Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 25th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.
Read Our Latest Stock Report on Arcadia Biosciences
Arcadia Biosciences Price Performance
Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The basic materials company reported ($2.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($1.53). The company had revenue of $1.44 million during the quarter, compared to analyst estimates of $1.90 million. Arcadia Biosciences had a negative return on equity of 183.50% and a negative net margin of 234.53%.
Arcadia Biosciences Company Profile
Arcadia Biosciences, Inc, founded in 2002 and headquartered in Davis, California, is an agricultural biotechnology company dedicated to developing crops and food ingredients that promote health and sustainability. By harnessing advanced genomics and precision‐breeding technologies, Arcadia creates proprietary trait platforms designed to enhance crop performance, nutritional value, and resilience to environmental stressors. The company’s scientific expertise focuses on non-transgenic approaches, enabling the delivery of novel traits without introducing foreign DNA.
Arcadia’s operations span two main segments: Crop Traits and Food Ingredients.
Recommended Stories
- Five stocks we like better than Arcadia Biosciences
- Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal
- GE Aerospace’s $11.75B Deal Puts Howmet Aerospace in Focus
- Casey’s Post-Earnings Drop May Give Investors a Better Entry Into a Quality Retailer
- Sovereign AI: Palantir and Nebius Cut the Cloud Cord
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
